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Supplementary
. Sequence alignment of CH3 domain of human IgG isotype antibodies (hIgG1, hIgG2, hIgG3, hIgG4) with highlights of the mutated residues in EW-RVT heterodimeric Fc variant (K360E/K409W CH3A -Q347R/D399V/F405T CH3B ) in comparison with the reported KiH (T366S/L368A/Y407V CH3A -T366W CH3B ) (1, 2), DD-KK (K409D/K392D CH3A -D399K/E356K CH3B ) (3) , and HA-TF (S364H/F405A CH3A -Y349T/T394F CH3B ) heterodimeric Fc variants, as indicated with each color code. The inverted arrows on the top indicate the 23 residues located in the homodimeric CH3-CH3 interface within the distance limit of 4.6 Å, analyzed using the human IgG1 Fc crystal structure (PDB code 3AVE) (4) . The amino acids are numbered by the EU nomenclature (5). quantified by measuring tubule extensions from endothelial cell bodies, to determine tubule length (6), using Image pro plus (Media Cybermetics, USA). Tubule length was measured as an average of three fields of view in each well for the two independent experiments. Error bars, ± SD. **P < 0.005. In (A and B) , the combined treatment with msMet and tanibirumab at the equivalent molar ratio are indicated as M+T. 
Fc proteins
Purification yield b ( mg/100-mL of transfected cells)
Fc-WT 2.9 ± 0.6
Fc-EW-RVT 2.9 ± 0.3
Fc-KiH 2.6 ± 0.5 a The two Fc plasmids carrying the CH3 wild type (WT) or variant pairs were co-transfected at the equivalent molar ratio into HEK293F cells in 100-mL culture volume following the standard protocol (7). After 6 day culture, Fc proteins were purified from the cell culture supernatant using protein A affinity column.
b
The values represent mean ± SD of four independent experiments. a Each value represents the mean ± SD of two independent experiments. In each experiment, at least 5 data sets were used in the determination of the kinetic constants. The representative sensograms are shown in Supplementary Fig. S3 . 
Supplementary Materials and Methods
Reagents
Design and evaluation of heterodimeric Fc
We identified candidate mutation pairs at the CH3-CH3 interface (3) and evaluated for the feasibility to stabilize Fc heterodimerization and destabilize Fc homodimerization based on the structural analysis of the 2 Å human IgG1 Fc crystal structure (PDB code 3AVE) (4). Each substitution was modeled in the 3AVE structure by optimizing side-chain conformations of the mutated residue and its surrounding residues in PyMol software (DeLano Scientific LLC).
Fc heterodimerization was screened using the scFv-Fc CH3A /Fc CH3B expression system ( Fig.   2A ) (3) . The human IgG1 Fc containing the hinge-CH2-CH3 (residues 225 -447 in EU numbering (5)) was subcloned into the mammalian expression vector pcDNA 3.1 (Invitrogen), generating a Fc CH3B expression plasmid ( Supplementary Fig. S2A ). The human AY4 scFv specifically recognizing human death receptor 4 (9) was in frame subcloned into the N-terminus of human IgG1
Fc, generating scFv-Fc CH3A expression plasmid ( Supplementary Fig. S2A ). DNAs encoding the designed CH3 variant pair of CH3A and CH3B were synthesized (Bioneer, Korea) and subcloned into XhoI/BamHI sites of the scFv-Fc CH3A (hAY4 scFv-hinge-CH2-CH3A) and Fc CH3B (hinge-CH2-CH3B) plasmids ( Fig. 2B and Supplementary S2A).
Construction, expression, and purification of antibodies
For the expression in Fc CH3A /Fc CH3B heterodimer, EW-RVT and KiH CH3 variant pair was subcloned using XhoI/BamHI into the corresponding CH3 region of Fc in pcDNA3.1 plasmid ( Supplementary   Fig. S2A ), generating two plasmids encoding Fc-EW-RVT proteins (hinge-CH2-CH3A (EW) × hinge-CH2-CH3B (RVT)) (Fig. 3A) .
For the construction of the msMet antibody in the format of Fv-Fc (VH-hinge-CH2-CH3A
(EW) × VL-hinge-CH2-CH3B (RVT)), the variable heavy (VH) and light (VL) sequence from MetMab (OA5D5, Genentech) (10, 11) was synthesized and subcloned into the N-terminus of Fc heterodimer (Fig. 4A) . For the generation of anti-Met × VEGFR-2 bsVeMet antibody in the format of scFv-Fc (anti-Met scFv-hinge-CH2-CH3A (EW) × anti-VEGFR-2 scFv-hinge-CH2-CH3B (RVT)), the anti-Met and VEGFR-2 scFv antibodies, generated by linking VH and VL sequences derived from the anti-Met OA-5D5 (10, 11) and anti-VEGFR-2 tanibirumab (8), respectively, with a (G 4 S) 3 peptide linker, were subcloned into the N-terminus of Fc heterodimer (Fig. 4A ).
Each pair of the two plasmids encoding Fc heterodimer, msMet and bsVeMet antibodies was transiently co-transfected at the equivalent molar ratio into HEK293F cells in FreeStyle 293 media, ranged from 100-ml to 400-ml liter culture volume, following the standard protocol (7). After 6 days of cultures, the antibodies were purified from the culture supernatants as described above and extensively dialyzed to resuspend in PBSG buffer (PBS plus 10% glycerol, pH 7.4). The antibodies concentrations were determined using a BCA protein assay (Pierce).
SEC analysis
SEC analysis was performed on the Agilent 1100 high performance liquid chromatography system using a Superdex TM 200 10/300 GL (10 mm × 300 mm; GE Healthcare) size exclusion column with a 13 mobile phase of PBS buffer (pH 7.4) at a flow rate 0.5 mL/min, as described previously (9) . All antibodies were analyzed at a concentration of 0.5 mg/mL in a sample volume of 100 μL.
Chromatograms were obtained by monitoring the absorbance at 280 nm. The apparent molecular mass of samples was estimated by fitting the elution volume into the calibration curve obtained from running of molecular mass standard markers (alcohol dehydrogenase, 150 kDa; bovine serum albumin, 66 kDa; carbonic anhydrase, 29 kDa) (Sigma-Aldrich). 
Far-UV CD spectroscopy
Differential scanning calorimetry (DSC)
DSC was performed using a MicroCal VP-DSC Microcalorimeter (GE Healthcare). Fc proteins (2.5 mg/mL (~50 μM) in 10 mM Tris, 10 mM NaCl buffer (pH 8.0)) were heated from 25°C to 95°C at a heating rate of 1.5°C/min. After subtraction of the buffer reference scan, sample thermogram was fitted into a two-state transition model to capture the melting temperatures (T m ) of CH2 and CH3 domains in the Origin 7.0 graphing software supplied by MicroCal.
SPR analysis
Kinetic binding interactions of antibodies or Fc proteins to target proteins (Met-Fc, VEGFR-2-Fc, FcγRs, and FcRn) were determined at 25°C by a Biacore 2000 SPR biosensor (GE Healthcare), as described before (13) . The target proteins at a concentration of 20 μg/mL in sodium-acetate buffer (pH 4.0) was immobilized onto the CM5 chip at a level of about 1,000 response units (RUs). Before loading the analytes, the chip was equilibrated with HBS-EP buffer (10 mM HEPES, 150 mM NaCl, In the assay monitoring the simultaneous binding interactions, bsVeMet (100 nM) was first flowed over VEGFR-2-Fc-immobilized surface (~1000 RU) at 30 μL/min for 3 min and then, without the dissociation phase, a second protein (Met-Fc or VEGFR-2-Fc at 100 nM) in HBS-EP buffer was immediately injected at 30 μL/min for 3 min (13).
Sandwich ELISA
The indicated antibodies (3 μM) were first incubated for 1 h with plate-coated VEGR2-Fc (1 μg/well) in 96-well plates (SPL, Korea). After washing with PBST (PBS plus 0.1% Tween-20), serially diluted 6×His-tagged human Met-Fc (0.16 -100 nM) was added and incubated at room temperature for 1 h. Bound Met-Fc protein was detected using mouse anti-His tag antibody (IG Therapy, Korea) and alkaline phosphatase conjugated goat anti-mouse antibody with the substrate of p-nitrophenyl phosphate (Sigma-Aldrich) (13) . Absorbance at 405 nm was read with a VersaMax microplate reader (Molecular Devices, Crawley, UK).
Flow cytometry
Cell surface expression levels of Met and VEGFR-2 were determined by flow cytometry after indirect immunofluorescent labeling using mouse anti-Met (Cell Signaling) and anti-VEGFR-2 antibody (Abcam), respectively, followed by FITC-conjugated anti-mouse IgG (PIERCE) (14) . Binding of msMet, tanibirumab, and bsVeMet antibodies to HUVEC and MKN45 cells were determined by 15 labeling cells with 100 nM antibodies for 1 h and then secondary labeling with FITC-conjugated antihuman IgG Fc antibody (Sigma) before flow cytometric analysis.
Cell proliferation assay
HUVECs, seeded at a density of 0.4 × 10 4 cells/well in 96-well plates, were incubated at 37°C in complete media for 24 h. Then, cells were starved using EBM-2 medium for 4 h prior to treatments of HGF (50 ng/mL), VEGF (20 ng/mL), and/or the antibodies, as specified in the figure legend.
MKN45 cells, seeded at a density of 0.6 ×10 4 cells/well in 96-well plates, were incubated at 37 °C in complete media for 24 h. Then, cells were serum-starved using free FBS RPMI1640 for 6 h before treatments of HGF (50 ng/mL) and/or the antibodies, as specified in the figure legend. Cell viability was analyzed using the MTT assay kit (Sigma-Aldrich) and the results are presented as the percentage of viable cells versus the medium-treated control or the corresponding control (12, 14) .
Western blots
HUVECs were cultured for 6 h in serum-free medium, then pretreated with antibodies (0.3 μM) at 37°C for 1 h, and then with or without HGF (10 or 20 ng/mL) and/or VEGF (10 or 20 ng/mL) at the indicated concentrations for 10 min (15) . MKN45 cells were cultured overnight in serum-free medium, then pretreated with antibodies (0.3 μM) at 37°C for 2 h, and then treated with or without HGF (20 ng/mL) for 10 min. Whole cell lysates were extracted using RIPA buffer (Biosesang), and protein concentrations were determined using Bicinchoninic Acid (BCA) Kit (Sigma). Western blotting for cell lysates treated as specified in figure legends was performed following the standard procedure (14) . Proteins were visualized using a PowerOpti-ECL western blotting detection reagent (Animal Genetics, Inc. Korea) and an ImageQuant LAS 4000 mini (GE Healthcare, Piscataway, NJ) (16) . Equal amount of cell lysates were analyzed by western blotting with β-actin as a loading control.
Animal experiments
All animal experiments were evaluated and approved by the Animal and Ethics Review . The statistical significance was evaluated by one-way analysis followed by two-tailed student t tests on Excel Software (Microsoft Inc.).
Immunofluorescence of tumor tissues
A single, equivalent molar dose of antibodies (200 μL of 3.1 μM per injection) was intravenously injected into mice carrying MKN45 xenografted tumors with an average size of ~7-8 mm in diameter.
Tumor tissues were harvested 5 or 24 h postinjection. Tumor preparation and staining of the cryosections were performed as described before (17, 18) . Briefly, the excised tumors from mice were fixed in 4% Paraformaldehyde (PFA) overnight at 4°C, cryo-protected in 30% sucrose for 10 h and then frozen in Tissue-Tek OCT (Optimal Cutting Temperature) embedding medium. For immunofluorescence staining, cryosections were prepared at 10 μm thickness and incubated with blocking solution (2% BSA in PBS) for 1 h at 25°C. Tissue sections were stained with rat antimouse CD31 mAb (BD Biosciences) at 4°C overnight, washed 2× with PBST (PBS containing 0.1% Tween20) and then stained with goat anti-rat TRITC-conjugated antibodies (Millipore) and FITCconjugated anti-human IgG Fc antibody (Sigma) at 25°C for 1.5 h. Slides were then washed 3× with
